Get the Stockscreener App
174.00
1.30%
2.24
After Hours:
174.31
0.31
+0.18%
Icon Plc stock is traded at $174.00, with a volume of 671.29K.
It is up +1.30% in the last 24 hours and down -6.96% over the past month.
Icon is a global late-stage contract research organization that provides drug development and clinical trial services to pharmaceutical, biotechnology, and medical-device firms. While the vast majority of its revenue comes from clinical research, Icon also offers ancillary services such as laboratory and imaging capabilities. The company is headquartered in Ireland.
See More
Previous Close:
$171.76
Open:
$171.86
24h Volume:
671.29K
Relative Volume:
0.53
Market Cap:
$14.05B
Revenue:
$8.19B
Net Income/Loss:
$758.19M
P/E Ratio:
18.95
EPS:
9.18
Net Cash Flow:
$1.06B
1W Performance:
-3.47%
1M Performance:
-6.96%
6M Performance:
-8.24%
1Y Performance:
-46.63%
1-Day Range:
$169.99
$174.73
1-Week Range:
$169.99
$181.51
52-Week Range:
$125.10
$328.04
Icon Plc Stock (ICLR) Company Profile
Compare ICLR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ICLR
Icon Plc
|
174.00 | 13.36B | 8.19B | 758.19M | 1.06B | 9.18 |
|
TMO
Thermo Fisher Scientific Inc
|
488.12 | 184.46B | 43.21B | 6.58B | 6.17B | 17.29 |
|
DHR
Danaher Corp
|
205.00 | 147.69B | 24.01B | 3.41B | 4.86B | 4.70 |
|
IDXX
Idexx Laboratories Inc
|
640.86 | 51.34B | 4.04B | 985.66M | 774.34M | 12.01 |
|
A
Agilent Technologies Inc
|
118.69 | 33.60B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
188.80 | 31.92B | 15.70B | 1.24B | 2.01B | 6.91 |
Icon Plc Stock (ICLR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-21-25 | Downgrade | Citigroup | Buy → Neutral |
| Jul-24-25 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Apr-29-25 | Downgrade | JP Morgan | Overweight → Neutral |
| Apr-14-25 | Downgrade | TD Cowen | Buy → Hold |
| Apr-10-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Mar-21-25 | Downgrade | Goldman | Buy → Neutral |
| Jan-07-25 | Initiated | RBC Capital Mkts | Outperform |
| Oct-24-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Oct-14-24 | Initiated | Redburn Atlantic | Neutral |
| Sep-18-24 | Initiated | Leerink Partners | Outperform |
| Jun-06-24 | Initiated | Goldman | Buy |
| Dec-15-23 | Initiated | Truist | Buy |
| Sep-13-23 | Initiated | TD Cowen | Outperform |
| Jan-17-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Jan-13-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Nov-09-22 | Upgrade | BofA Securities | Neutral → Buy |
| Sep-07-22 | Initiated | UBS | Buy |
| Aug-25-22 | Initiated | Credit Suisse | Neutral |
| May-24-22 | Initiated | Guggenheim | Buy |
| Apr-25-22 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-12-22 | Upgrade | Deutsche Bank | Hold → Buy |
| Sep-27-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Aug-05-21 | Resumed | Credit Suisse | Outperform |
| Jul-23-21 | Upgrade | Citigroup | Neutral → Buy |
| Jul-14-21 | Initiated | Citigroup | Neutral |
| Apr-13-21 | Resumed | BofA Securities | Neutral |
| Apr-01-21 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-08-21 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Mar-03-21 | Initiated | Barclays | Equal Weight |
| Mar-01-21 | Upgrade | UBS | Neutral → Buy |
| Feb-26-21 | Upgrade | Truist | Hold → Buy |
| Jul-24-20 | Downgrade | BofA Securities | Buy → Neutral |
| Apr-20-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Mar-26-20 | Upgrade | Barclays | Equal Weight → Overweight |
| Mar-02-20 | Initiated | Deutsche Bank | Hold |
| Jan-27-20 | Downgrade | SunTrust | Buy → Hold |
| Jan-08-20 | Initiated | Wells Fargo | Equal Weight |
| Jan-07-20 | Initiated | Citigroup | Neutral |
| Sep-23-19 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| Jul-26-19 | Upgrade | UBS | Sell → Neutral |
| Jan-25-19 | Upgrade | Mizuho | Neutral → Buy |
| Oct-26-18 | Upgrade | Evercore ISI | In-line → Outperform |
| Oct-09-18 | Initiated | UBS | Sell |
| Apr-03-18 | Downgrade | Evercore ISI | Outperform → In-line |
| Feb-15-18 | Reiterated | Mizuho | Neutral |
| Jan-19-18 | Initiated | Evercore ISI | Outperform |
| Oct-27-17 | Reiterated | Barclays | Equal Weight |
| Sep-11-17 | Initiated | BofA/Merrill | Buy |
| Jul-31-17 | Upgrade | SunTrust | Hold → Buy |
| Jul-27-17 | Reiterated | Mizuho | Neutral |
| Jun-29-17 | Upgrade | Jefferies | Hold → Buy |
View All
Icon Plc Stock (ICLR) Latest News
AstraZeneca and Icon Plc’s Study on ATTR Amyloidosis: Key Insights for Investors - TipRanks
ICON plc Releases Interim Financial Statements for 2025 - TipRanks
ICON Properties Plc (Malawi) declared a final dividend of 0.15 MWK per share - AfricanFinancials
Earnings call transcript: ICON plc beats Q2 2025 earnings expectations - Investing.com
Citi Downgrades Icon PLC(ICLR.US) to Hold Rating, Cuts Target Price to $200 - 富途牛牛
ICON plc Halts COVID Vaccine Study Due to BARDA Stop Work Notice - AInvest
Healthcare Sector Rebound: Is Now the Time to Buy High-Quality CROs Like ICON? - AInvest
ICON suspends COVID vaccine study after BARDA notice - MSN
Icon Plc (NASDAQ:ICLR) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World
Icon Suspends COVID Vaccine Study After BARDA Notice, Impacting H2 2025 Revenue - AInvest
ICON plc Halts COVID Vaccine Study Following BARDA Notice - MSN
Icon PLC Shares Jump 4.26% on $250M Volume as Analysts Target 25% Gains Despite 462nd Rank - AInvest
BARDA Stops ICON COVID Vaccine Study, Company Suspends New Enrollments - AInvest
ICON suspends COVID vaccine study after BARDA notice to sponsor - Seeking Alpha
ICON plc Provides Update on Vaccine Study - MarketScreener
ICON (ICLR) Fell Along with Broader CROs - Insider Monkey
ICON plc (ICLR) Fell due to Persistent Volatility in the Clinical Development Market - Insider Monkey
ICON plc (ICLR) stock fell due to persistent volatility in the clinical development market. - AInvest
Arkadios Wealth Advisors Purchases 6,666 Shares of Icon Plc (NASDAQ:ICLR) - Defense World
Fund Update: First Pacific Advisors, LP added 417,173 shares of ICON PLC ($ICLR) to their portfolio - Quiver Quantitative
ICON Plc’s Earnings Call: Balancing Achievements and Challenges - TipRanks
ICON plc: Initiation of Coverage- Capitalizing On Opportunities in China, A Critical Growth Market! - smartkarma.com
ICON Plc's Q2 Earnings Call: Balancing Growth and Challenges - AInvest
Deutsche Bank Maintains Icon PLC(ICLR.US) With Buy Rating, Cuts Target Price to $210 - 富途牛牛
Leerink Partners Maintains Icon PLC(ICLR.US) With Buy Rating, Maintains Target Price $240 - 富途牛牛
ICON plc’s SWOT analysis: navigating challenges in CRO stock landscape By Investing.com - Investing.com India
ICON plc’s SWOT analysis: navigating challenges in CRO stock landscape - Investing.com
ICON's Intrinsic Value Estimated at $278, 33% Undervalued by Current Share Price - AInvest
Thermo Fisher, Baker Hughes And IQVIA Holdings Are Among Top 10 Large Cap Gainers Last Week (July 21-July 25): Are The Others In Your Portfolio? - Benzinga
Icon price target raised to $225 from $173 at Mizuho - TipRanks
ICON plc Q2 2025 Financial Results: Revenue Up 0.8%, Net Income Rises 30.7% - AInvest
UBS Raises Icon PLC Price Target to $240, Maintains 'Buy' Rating - AInvest
Icon PLC (ICLR) Sees Price Target Boost Amid Stable Booking Trends - AInvest
ICON plc Reports Strong Q2 2025 Financial Results - The Globe and Mail
ICON plc Expands Share Repurchase Program and Resumes COVID Vaccine Study - The Globe and Mail
ICON plcOrdinary Shares (Nasdaq:ICLR) Stock Quote - FinancialContent
Evercore Maintains Icon PLC(ICLR.US) With Buy Rating, Maintains Target Price $240 - 富途牛牛
A Quick Look at Today's Ratings for Icon PLC(ICLR.US), With a Forecast Between $209 to $240 - 富途牛牛
Icon PLC (ICLR) Q2 2025 Earnings Call Highlights: Navigating Challenges with Strategic Wins - GuruFocus
Icon PLC (ICLR) Q2 2025 Earnings Call Highlights: Navigating Cha - GuruFocus
Icon plc's Shares Surge 17.2% Amid Investor Optimism - AInvest
Icon Plc Announces Kedrion IVIg 10% Study for Chronic ITP: Market Implications - AInvest
ICON Expects $8B in Revenue for Full Year, Driven by Biotech Wins and Pharma Partnerships - AInvest
ICON plc Announces Successful AGM Resolutions - The Globe and Mail
ICON Stock Surge: Future Safe or Risky? - StocksToTrade
ICON’s Unexpected Surge: What’s Behind the Jump? - timothysykes.com
ICON Stock Up After Q2 Results Signal Growing Confidence In Biopharma Recovery - Benzinga
A Quick Look at Today's Ratings for Icon PLC(ICLR.US), With a Forecast Between $170 to $224 - 富途牛牛
Icon plc (ICLR) Shares Surge Over 17% Amid Investor Optimism | ICLR Stock News - GuruFocus
Icon Plc’s New Study on Kedrion IVIg 10% for Chronic ITP: What Investors Need to Know - TipRanks
ICON’s Earnings Beat and Strategic Moves: A Market Outlook - StocksToTrade
Icon Plc Stock (ICLR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.51%
0.31%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):